Devirex specialises in developing, registering and marketing novel dermatological solutions and products for the treatment of personal care issues. Devirex has developed a product that can prevent the appearance of cold sores (herpes simplex virus, HSV-1). In parallel with the international launch of the cold sore product, the company is investing resources in research and development targeting additional products and solutions, the Development Portfolio. Devirex has more than 60 shareholders and plan to list the company’s share on Nasdaq First North during the fourth quarter of 2018. The ISIN-code of the Company's shares is CH0321028612.
+41 41 758 00 00